|
|
Post by wyattdog on May 1, 2024 15:05:06 GMT -5
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2024 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 8, 2024. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram. For MannKind: Rose Alinaya, Investor Relations (818) 661-5000 Email: ir@mannkindcorp.com |
|
|
|
Post by bthomas55ep on May 2, 2024 10:12:22 GMT -5
Curious if anybody has a swag at the Q1 earnings picture now that UTHR has report? Does the company keep that positive eps in this quarter ($.02 or even $.03 per share) or too much spent on getting the trials ready? Several here on proboards are very good at putting these projections together. Thanks!
|
|
|
|
Post by peppy on May 2, 2024 10:22:50 GMT -5
|
|
|
|
Post by bthomas55ep on May 2, 2024 10:29:06 GMT -5
Thanks Peppy - How about Revenue thoughts from the board? |
|
|
|
Post by akemp3000 on May 2, 2024 10:36:26 GMT -5
$60.49M in revenue. This is the analysts average, not my guess. It would be interesting to see and hear what the board thinks.
|
|
|
|
Post by parrerob on May 2, 2024 13:01:28 GMT -5
Here I am.... considering q4 was positively unexpected specially regarding coll&service and afrezza (thinking about what we knew from Symphony till November) I wll be happy with 60 m$.... practically considerig Afrezza quite equal to q4, vgo and coll&service as well....
2 m$ more from Tyvaso dpi.
Anythink more will be wellcome.
|
|
|
|
Post by centralcoastinvestor on May 2, 2024 13:08:27 GMT -5
It appeared to me that Afrezza was gaining a little more traction at the end of last year. Then the data for Afrezza prescriptions became unavailable. I actually thought that the first week where we lost data access, we were going to see a 1000 scripts for the first time. I have a secret hope that Afrezza revenue surprises to the upside.
|
|
|
|
Post by porkini on May 2, 2024 13:20:02 GMT -5
I wonder if it's time to plan our earnings report before UTHR. Let's see the bump just based on MNKD reporting. I think UTHR is big/well-known enough that the market will still pay attention to them if they report after MNKD.
|
|
|
|
Post by ktim on May 2, 2024 13:42:37 GMT -5
It appeared to me that Afrezza was gaining a little more traction at the end of last year. Then the data for Afrezza prescriptions became unavailable. I actually thought that the first week where we lost data access, we were going to see a 1000 scripts for the first time. I have a secret hope that Afrezza revenue surprises to the upside. Warning: tongue in cheek follows The MNKD short cabal is vicious and powerful... taking down Symphony data for all drugs just to cover up the fact we finally hit 1000 per month  |
|
|
|
Post by cretin11 on May 2, 2024 13:48:18 GMT -5
They are vindictive boogiemen whose tentacles reach far and wide, powerful enough to shut down Symphony right before the 1000 TRx milestone. And why? Just to prevent the impending celebration on ProBoards. They will stop at nothing to keep us down and thwart our happiness. 🤬
|
|
|
|
Post by cretin11 on May 2, 2024 13:53:00 GMT -5
I have a secret hope that Afrezza revenue surprises to the upside. We all have that same hope and it’s not a secret. The question is, do you have that secret belief in such a surprise to the upside? I personally think we have finally topped the 1000 TRx mark but I don’t expect Mike to confirm such a milestone. Not because he’s being coy but because it would be embarrassing to even mention such a low bar. So my hope is he doesn’t mention weekly TRx but I share your hope of the surprise in revenue to the upside. We can all then have fun extrapolating TRx etc. |
|
|
|
Post by prcgorman2 on May 7, 2024 8:06:59 GMT -5
Thanks BD for pointing me to this thread. I like the analyst consensus average and am cautiously hopeful MNKD meets or exceeds $60M. I know we're 18 mos. away (at least) from Clofazimine approval and marketing, but I would kind of like to hear what Mike and team have in mind for marketing the drug. The orphan drug designation and fast track grant from the FDA is all good news but I've no idea how any company should market an important new drug therapy (inhalable Clofazimine) to the ~225,000 primary care physicians serving the less than 150,000 (IIRC) NTM sufferers here in the U.S.. MannKind has hinted about a partnership with a Japanese pharma (forget the name), so I'm expecting a marketing agreement and something similar to the collaboration/services + royalties there, but don't know about U.S., and rest of world. Good luck to all MNKD longs! |
|
|
|
Post by Clement on May 7, 2024 8:33:30 GMT -5
^Might the Japanese pharma be Mochida Pharmaceuticals? That's the company UTHR dealt with to take nebulized Tyvaso to Japan. This is discussed in the UTHR tgread.
|
|
|
|
Post by dh4mizzou on May 7, 2024 11:35:35 GMT -5
Man, tomorrow afternoon can't get here soon enough. Argh.
|
|
|
|
Post by BD on May 7, 2024 13:53:30 GMT -5
Man, tomorrow afternoon can't get here soon enough. Argh. |
|
